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Background. Several polymorphisms of a locus on chromosome 1p13.3 have a significant effect on low-density lipoprotein cholesterol
(LDL-C), atherosclerosis, and acute coronary syndrome (ACS).Methods.We aimed to investigate the association between rs599839,
rs646776, and rs4970834 of locus 1p13.3 and serum LDL-C and severity of coronary artery stenosis in ACS patients. Genotyping of
the rs599839, rs646776, and rs4970834 polymorphismswas performed onArab patients undergoing coronary angiography forACS.
Patients were divided into groupA (ACSwith insignificant stenosis (<50%)) and group B (with significant stenosis (≥50%)).Results.
Patients carrying the minor G allele in rs599839 had significantly lower mean of LDL-C (2.58 versus 3.44mM, 𝑃 = 0.026) than
homozygous A allele carriers (GG versus AA). Carriers of minor C allele in rs64776 had significantly higher mean of HDL-C (2.16
versus 1.36mM, 𝑃 = 0.004) than carriers of the T alleles (AA versus GG). The odd ratio and 95% confidence interval for dominant
model for G allele carriers of rs599839 were 0.51 (0.30–0.92), 𝑃 = 0.038, among patients with significant stenosis. Conclusions.
Polymorphisms rs646776 and rs599839 of locus 1p13.3 were significantly associated with LDL-C and other lipid parameters. In
addition, the G-allele carriers of variant rs599839 had a significant protective effect against the atherosclerosis.
1. Introduction
Cardiovascular disease (CVD) is a leading cause of morbidity
and mortality worldwide [1]. Serum LDL cholesterol has
a contributing role in the pathogenesis of cardiovascular
diseases [2]. Clinical and epidemiological studies showed
that increased levels of low-density lipoprotein cholesterol
(LDL-C) promote premature atherosclerosis [3, 4]. Low-
density lipoprotein cholesterol, the major carrier of blood
cholesterol, has been implicated in the buildup of choles-
terol in atherosclerotic plaques. Several mechanisms were
postulated to explain the role of LDL in the pathogenesis of
atherosclerosis. Oxidation of LDL-C has been shown to result
in numerous changes in its biologic properties that could
have pathogenetic importance, including accelerated uptake
in macrophages, cytotoxicity, and chemotactic activity for
monocytes in arterial walls [5, 6]. It has also been shown that
subjects with small dense LDL-C particles show an impaired
response to the endothelium-dependent vasodilator acetyl-
choline [7]. Experimental studies have demonstrated that
decreasing serum LDL cholesterol concentrations have a
clinical effect on the CVDmorbidity and mortality [8]. Thus,
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regulation of LDL cholesterol represents an important tar-
get for developing additional interventional approaches to
decrease the hazards of CVD.
Coronary artery disease (CAD) as a consequence of the
atherosclerotic changes in coronary arteries may also result
from the action ofmultiple genetic and environmental factors
[9]. Genetic susceptibility to ischemic heart diseases (IHD)
may be determined by specific polymorphic variants of genes
encoding isoform involved in processes that are important in
the pathogenesis of atherosclerosis.
Recently, genome-wide association studies (GWAS)
reported a number of candidate loci conferring risk or pro-
tection from CAD and myocardial infarction (MI) [10, 11].
Recent genome-wide association studies (GWAS) have
discovered a significant association of hypercholesterolemia
and myocardial infarction with polymorphisms on human
chromosome 1p13.3. There are four genes in this region
proline/serine-rich coiled-coil protein 1 (PSRC1), cadherin,
EGF LAG seven-pass G-type receptor 2 (CELSR2), myosin
binding protein H-like (MYBPHL), and sortilin 1 (SORT1)
[12].
An intracellular receptor for apolipoprotein (apo) B100
known as sortilin is encoded by SORT1. It interacts with
apoB100 in the Golgi apparatus and accelerates the hepatic
synthesis and export of apoB100-containing lipoproteins, and
so it regulates the circulating level of LDL-C. It has been
shown that knockout mouse of sortilin receptor reduces
secretion of lipoproteins from the liver and reduce the hyper-
cholesterolemia and atherosclerotic plaques development in
LDL receptor-deficient animals. In contrast, overexpression
of sortilin accelerates hepatic release of lipoproteins and
increases the circulating LDL levels [13].
The promising candidate loci on chromosomal location
1p13.3 have been linked consistently to LDL-C in all genetic
association studies that examined this parameter [11, 13–15],
which is a well-established risk factor for CAD [12].
GWAS showed the following variants rs599839, rs646776,
and rs4970834 on chromosomal location 1p13.3 as genetic
determinants of LDL metabolic parameters [14–16]. It has
been successfully replicated in several studies [15–17]; how-
ever, one study has shown no association with CAD [18].
These polymorphisms are located on 1p13.3 in an approx-
imately 97KB large block of linkage disequilibrium. The
variant rs599839 located in the 3- untranslated region of
the PSRC1 gene shows strong linkage disequilibrium with
other SNPs in this LD block [12]. In particular, rs599839
is the SNP that has the highest correlation with CAD and
LDL-C in most studies [14, 15, 19, 20]. The minor allele
in European populations (G, MAF0.33 in HapMap CEU;
http://www.ncbi.nlm.nih.gov/projects/SNP/) was found to
be associated with a lower risk of CAD and lower levels of
LDL-C.
There are currently no equivalent data of such relation-
ship among Arab population that evaluated the polymor-
phisms of genes modulating LDL-C level and its impact on
CAD.The aim of this study is to investigate the associations of
the SNPs: rs599839, rs646776, and rs4970834 of 1p13.3 locus
with (1) serum LDL cholesterol, (2) other lipid profile, and
(3) its value as risk factors of CAD (with and without LDL) in
a cohort of well-characterized consecutive patients presented
with acute coronary artery syndrome (ACS) that underwent
coronary angiography.
2. Methods
2.1. Subjects. A case-control association studywas performed
on 227 consecutive Arab patients, who had been admit-
ted with ACS to coronary care unit at Hamad Medical
Corporation (HMC). Cardiovascular risk factors such as
hypertension, obesity, diabetes, and smoking were obtained.
Blood samples were collected after 12 hours overnight fasting.
The diagnosis of ACS was made by the attending physicians
according to American College of Cardiology, American
Heart Association (ACC/AHA) standards [21]. Type 2 dia-
betes was diagnosed according to the ADA criteria [22].
Dyslipidemia was identified based on the standards of the
National Cholesterol Education Program Adult Treatment
Panel III [23]. The cut-off points for body mass index
(BMI) were used to define obesity according to world health
organization “WHO” criteria [24].
All patients underwent coronary angiograms on the
index admission. Two physicians assessed the degree of
atherosclerotic lesions, and the number of coronary vessels
affected. Males and females patients aged between 30 and
70 years were divided into two groups based on the extent
of the atherosclerotic lesions, which were assessed by the
angiographic data. The degree of atherosclerotic lesions and
number of coronary vessels affected were assessed. Patients
were categorized according to their coronary angiographic
findings, that is, group A: with nonsignificant atherosclerotic
lesion (<50% stenosis, insignificant lesion used as a control
group, 𝑛 = 91) and group B: atherosclerotic lesion causing
luminal stenosis ≥50% (significant stenosis and used as a case
group, 𝑛 = 136) [25]. Individuals with diseases such as cancer,
liver failure, renal failure, and autoimmune disorders were
excluded. Human subjects data were extracted from patients
recruited under protocols 12297 and 10043 that have been
approved by the MRC, HMC.
3. Measurements
3.1. Clinical Measurements. Height, weight, waist circum-
ference, and systolic and diastolic blood pressures were
measured. Weight and height were measured in Kg and
cm, respectively, down to one decimal point. Hypertension
was a systolic and/or diastolic blood pressure ≥140 and/or
≥90mmHg and/or a significant history of hypertension
and/or under treatment of hypertension. The body mass
index (BMI) was calculated by dividing the weight (Kg) over
the square of height (m2).
3.2. Biochemical Assays. 10mL of peripheral blood was
collected from each participating subject. 5mL was used
for DNA extraction, and the remaining 5mL was used
for determination of the biochemical parameters including
plasma glucose, lipid profile, and cardiac markers including
CK-MB and Troponin T. All biochemical assays were done
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at clinical chemistry labs at HMC-Qatar. Genetic analysis
was performed in the Biomedical Research Labs of Qatar
University.
3.3. Genotyping of the Polymorphisms of theVariants rs599839,
rs646776, and rs4970834. The genotyping was performed as
previously published [26]. In brief, DNA was extracted from
whole blood samples of all study subjects, using the QiaAmp
DNA blood Mini Kit Cat # 51360 (Qiagen, Germany) with
RBC lysis solution Cat # 158904 (Qiagen, Germany). It
was performed according to the manufacturer protocol.
Measurements of DNA concentration and purity were done
using the NanoDrop Spectrophotometer.
3.3.1. Gene Amplification. rs599839, rs646776, and rs4970834
variants are located in chromosomal locus 1p13.3. The basis
of the selection of theses SNPs was based on previous publi-
cations that indicated an association of these SNPs with the
lipid profile and CVD [14, 17, 18], and it has an impact on the
expression of SORT1, a nearby gene thatmediates endocytosis
and degradation of lipoprotein lipase [27]. Figure 1 shows
the genetic architecture of 1p13.3 locus and the linkage
disequilibrium (LD) between the 3 SNPs used in this study,
with values representing 𝑟2 values from hapview by golden
helix software program. All SNPs were genotyped by allele-
specific PCR, in which primers were designed to specifically
amplify the reference allele. Polymorphisms of these SNPs
were performed by the 5󸀠 nuclease assay using TaqMan
MGB probe by means of an ABI 7500 (Applied Biosystems,
Foster City, CA). The primers and the probes of these SNPs
polymorphisms were provided by the assay-on demand TM
service by (Applied Biosystems). The 5󸀠 nuclease assay was
performed using 20 ng genomic DNA, 1x TaqMan Universal
PCR Master Mix (Applied Biosystems), and 1x primer/probe
mix using the proper conditions for amplifications by the
manufacturer’s instructions and negative controls were used.
3.4. Statistical Analysis. Data were explored for outliers,
skewness, and normality and transformed when necessary
if the normality assumption was violated. Continuous data
are expressed as mean ± SD for normally distributed vari-
ables, median and interquartile range [25%–75%] for nondis-
tributed continuous data, and number and percentage for
categorical data. Two Student’s t-tests and nonparametric
Mann-Whitney evaluated the differences between continu-
ous variables, and 2 independent samples t-tests were used
accordingly for the analysis. Differences between categorical
variables were evaluated by chi-square test. Genotype dis-
tributions and allele frequencies between the study groups
were compared by constructing 2 × 2 contingency tables, 𝑥2,
and/or Fisher exact test corrected for Bonferroni adjustment
for the number of SNPs. The Hardy-Weinberg equilibrium
(HWE) was calculated using the chi-square test to determine
genotype distribution in all study subjects. Odds ratios (ORs),
95% confidence intervals (CIs), and corresponding 𝑃 values
for the samples were analyzed by logistic regression analysis.
ORs were computed using the minor homozygous alleles as
the reference group unless otherwise stated. Pairwise linkage
disequilibrium coefficients (D󸀠) and haplotype frequency
were estimated using the golden helix (SVS 8) software.
Multiple testing corrections were applied to avoid false
positive results such as with Bonferroni adjustments and
false discovery rate using Golden Helix software. Estimated
marginal means with 95% confidence interval of the lipid
parameters in association with genotypes were evaluated
utilizing general linear model adjusted for age, gender, BMI,
type 2 diabetes, smoking, hypertension, and lipid-lowering
therapy. Multiple step regression analysis was applied to
assess the associations between the LDL (dependent variable)
and the following independent variables: age, gender, BMI,
diabetes, hypertension and dyslipidemia, and antilipidemic
treatment and rs599839, rs646776, and rs4970834.
The biological interaction evaluates the alteration in the
hazard associated with the contact to both factors: circulating
LDL level and genotype. The biological interaction estimates
the difference in the risk, which is expressed as OR (95% CI)
when exposed to one factor alone or both factors together
[28]. The interaction between the genotypes and the serum
LDL-C was calculated using the biological approach [29].
The biological interaction estimates the difference in the
risk associated with the exposure to both factors. The ratio
between the risk observed in the presence of both factors and
the risk observed in the reference group can be used to drive
the synergy index (S) [30, 31].
All statistical analyses were performed using the SPSS
program for Windows (version 21 statistical software, Texas
Instruments, IL, USA), Graph Pad Prism (version 6, for
Mac, Graph Pad Software, La Jolla California USA), and
the Golden Helix SNP and Variation Suite (SVS 8, software;
Bozeman, MT, USA) for genetic analysis. Two-tailed 𝑃 value
< 0.05 is statistically significant.
3.5. Power Calculations. We carried out a statistical power
analysis using QUANTO software version 1.2 (http://hydra
.usc.edu/gxe/ vti bin/shtml.dll/request.htm) to ensure our
sample size is sufficient to identify associations of our SNPs
and their susceptibility with CAD/MI. Under the popula-
tion parameter settings, prior data indicated that MAF of
rs599839-G is 0.18 [32, 33] and setting of the odds-ratio of
0.55 and dominant model of inheritance [17], we need to
study 226 subjects to be able to reject the null hypothesis
that the rs599839-G rates for cases and controls are equal
with probability (power) of 0.8. The type I error probability
associated with this test of this null hypothesis is 0.05.
4. Results
4.1. Clinical, Biochemical, and Genetic Data of the Cardiac
Patients. Tables 1(a) and 1(b) show the clinical and bio-
chemical data collected from patients diagnosed with ACS
based on the angiographic data of the coronary arteries.
Among 227 subjects, 136 patients (60.0%) had significant
stenosis (≥50%) and 91 patients (40.0%) had insignificant
stenosis (<50.0%). Patients with significant stenosis (group
B) had a mean age (SD) of 56.33 (10.59) years while patients
with the insignificant stenosis (group A) had 56.36 (9.34)
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Figure 1: The genetic architecture of 1p13.3 and Linkage Disequilibrium (LD) of the rs599839, rs646776, and rs4970834 of on chromosomal
location 1p13.3 in ACS patients. Red diamonds represent pairwise LD “EMD󸀠” values between rs4970834 and rs646776 (upper left), rs646776
and rs599839 (upper right), and rs4970834, and rs599839 (lower), respectively.
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Table 1: (a) Clinical and biochemical data of cardiac patients. (b)
Coronary artery disease risks factors among the study subjects.
(a)
Variables Group (A)
𝑁 = 91
Group (B)
𝑁 = 136
𝑃 value
Age (years) 56.86 (9.34) 56.33 (10.59) 0.701
BMI (kg/m2) 31.69 (6.19) 30.57 (6.94) 0.897
Body weight (kg) 81.85 (26.17) 80.49 (27.79)
SBP (mmHg) 129.73 (16.38) 132.95 (21.84) 0.290
DBP (mmHg) 72.42 (10.21) 72.83 (9.95) 0.790
Glucose (mM) 6.94(5.47–8.41)
9.49
(8.15–10.83) 0.003
LDL (mM) 2.69(2.42–2.96)
2.81
(2.59–3.01) 0.510
HDL (mM) 1.01(0.94–1.11)
0.97
(0.92–1.04) 0.551
TC (mM) 4.61(4.25–4.97)
4.70
(4.19–5.22) 0.728
TG (mM) 2.58(1.45–3.07)
1.96
(1.71–2.21) 0.568
Troponin (ng/mL) 2.42(0.01–4.29)
3.53
(1.01–7.87) 0.130
CK-MB (ng/mL) 7.68(0.75–44.43)
34.53
(4.63–141.35) 0.082
Continuous data are presented as means (SD) for normally distributed
data and mean and lower and upper 95%, CI. Categorical variables were
presented as number and percent. BMI: body mass index, SBP: systolic
blood pressure, DSB: diastolic blood pressure, TC: total cholesterol, TG:
triglycerides, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-
density lipoprotein cholesterol, CK-MB: creatinine kinaseMBprotein. Two-
tailed 𝑃 value is significant at <0.05.
(b)
Variables
Group A
Nonsignificant
stenosis
Group B
Significant
stenosis
𝑃 value
CAD risk factors
(𝑁, %) 𝑁 = 91 (40%) 𝑁 = 136 (60%)
Gender
Male 68.0 (74.7%) 110.0 (80.9%) 0.269
Female 23.0 (25.3%) 26.0 (19.1%)
Obesity 45.0 (49.5%) 71.0 (52.2%) 0.736
Hypertension (yes) 54.0 (59.3%) 84.0 (61.7%) 0.842
DM (yes) 40.0 (43.8%) 65.0 (62.5%) 0.008
Dyslipidemia (yes) 28.0 (33.73%) 41.0 (32.80%) 0.885
Smoking (yes) 30.0 (32.9%) 63.0 (46.3%) 0.062
FH of CAD (yes) 22.0 (24.1%) 40.0 (29.4%) 0.465
Use antidiabetic
treatment 26.0 (28.6%) 40.0 (38.1%) 0.151
Use statin treatment 25.0 (34.2%) 38.0 (36.2%) 0.224
Categorical variables were presented as number and percent. DM: type 2
diabetes, FH of CAD: family history of coronary artery diseases. Two-tailed
𝑃 value is significant at <0.05.
years, with 𝑃 value = 0.701. Among patients with significant
stenosis: 80.9% were males, 52.2% were obese, 61.7% were
hypertensive, 62.5% were diabetic, 33.1% were dyslipidemic,
and 46.3% were smokers. Among patients with insignificant
stenosis: 74.7% were males, 49.5% were obese, 59.3% were
hypertensive, 43.8% were diabetic, 45.2% were dyslipidemic,
and 32.9%were smokers. Group (B) had a significantly higher
frequency of diabetes and higher fasting blood glucose than
group A (𝑃 = 0.008) and (𝑃 = 0.003), respectively. No
significant difference was found between groups A and
B for age; weight; BMI; gender; SBP; DBP; frequency of
hypertension; dyslipidemia; smoking; lipid profile (TC, TG,
HDL, and LDL); cardiac enzyme markers (troponin and CK-
MB); and antidiabetic and statin treatment, as shown in
Table 1.
In addition, overall the SNP genotypes and allelic fre-
quencies were determined in all individuals. The call rate of
all SNPs in this study was ≥90.0%, and genotype frequency
did not deviate significantly from the Hardy-Weinberg Equi-
librium (HWE) with 𝑃 value >0.05. Table 2 shows the
genotype distribution of rs599839, rs646776, and rs4970834
polymorphisms in all subjects and according to the degree
of the significant stenosis. There were a more frequent AA
(48.4%) genotype for rs599839, TT (76.9%) genotype for
rs646776, and CC (54.2%) genotype for rs4970834 among all
study subjects. Table 2 also presents the frequencies of minor
alleles in each SNP among all study subjects: G (0.434) for
rs599839, C (0.201) for rs646776, andT (0.369) for rs4970834.
Utilizing the chi-square test with corrections for Bonferroni
adjustments of SNPs numbers, only a significant association
was observed between the minor allele (G) of rs599839 and
the coronary artery stenosis 𝑃 = 0.032, 𝜒2 = 3.68. The minor
alleles of the other two SNPs rs646776 and rs4970834 were
not significantly associated with a significant coronary artery
stenosis among the study subjects as shown in Table 2.
4.1.1. Linkage Disequilibrium (LD) of the Three SNPs
(rs599839, rs646776, and rs4970834) in CAD Patients
(Figure 1). Pairwise LD between the 3 polymorphisms was
evaluated using data from all subjects. Using the expectation-
maximization (EM), the results of LD and the 𝑟2 for all study
subjects are presented in Figure 1. The results of the LD of
the three pairs had low LD in the study subjects. Therefore,
all SNPs rs599839, rs646776, and rs4970834 were included
in the analysis (Figure 1).
4.2. Association with the Lipid Profile
4.2.1. Associations of Genotypes with Lipid Parameters
(Table 3). Weassessed serum lipid concentrations (estimated
marginalmeanswith 95%CI)with respect to the genotypes of
the variants rs599839, rs64776, and rs4970834 using different
genetic models which were adjusted for age, gender, BMI,
type 2 diabetes, smoking, hypertension, and antidiabetic and
statin therapy. Patients carrying the G allele (GG versus AA)
in rs599839 variant had significantly lower mean TC levels
than A allele carriers (4.13 versus 5.29mM, 𝑃 = 0.041) and
mean LDL-C (2.58 versus 3.44mM, 𝑃 = 0.026), respectively.
Patients carriers of the C allele (CC versus TT) in rs64776
had significantly lower mean TG levels than T allele carriers
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Table 2: Frequency of genotypes and alleles among study subjects based upon the significance of coronary artery stenosis stratification in
CAD patients.
SNPs Genotype 𝑁 (%) Group AInsignificant stenosis
Group B
Significant stenosis 𝜒
2
𝑃
rs599839 A>G
AA 107 (48.4) 48 (56.5) 59 (43.4)
3.668 0.159AG 36 (16.3) 11 (12.9) 25 (18.4)
GG 78 (35.3) 26 (30.6) 52 (38.2)
MAF G (0.434) G (0.371) G (0.474) 3.682 0.032
rs646776 T>C
TT 170 (76.9) 73 (80.2) 97 (72.9)
1.568 0.456TC 18 (8.0) 6 (6.6) 12 (9.0)
CC 36 (16.1) 12 (13.2) 24 (18.1)
MAF C (0.201) C (0.165) C (0.236) 2.119 0.146
rs4970834 C>T
CC 122 (54.2) 48 (53.9) 74 (54.4)
4.147 0.125CT 40 (17.8) 11 (12.4) 29 (21.3)
TT 63 (28) 30 (33.7) 33 (24.3)
MAF T (0.369) T (0.425) T (0.316) 0.934 0.317
Data are presented by frequency for minor allele [MAF] and𝑃 value is significant at >0.05. Frequency of alleles is presented as a percentage. Data were analyzed
by chi-square test (2 degrees of freedom) with Bonferroni adjustments. Two-tailed 𝑃 value is significant at <0.05.
Table 3: Estimated marginal means (95% CI) of the lipid profile based upon the genotypes of the studied SNPs in all study subjects.
TC TG HDL-C LDL-C
rs599839 A>G-genotypes
AA 5.29 (3.92–6.81) 3.02 (0.85–6.09) 1.44 (0.84–1.93) 3.44 (2.92–3.90)
AG+GG 5.06 (4.21–5.92) 2.87 (0.75–6.72) 1.48 (0.99–1.86) 2.92 (2.27–3.65)
GG 4.13 (3.62–5.05) 2.68 (0.46–7.58) 1.58 (0.89–2.72) 2.58 (2.31–3.39)
AA+AG 4.53 (3.77–5.38) 3.49 (0.78–7.66) 1.46 (0.78–1.91) 2.74 (2.00–3.47)
AG 4.66 (3.17–5.38) 3.08 (0.79–7.63) 1.52 (0.78–2.26) 2.68 (2.21–3.77)
𝑃 value for rs599839 genotypes
GG vs. AA+AG 0.180 0.905 0.731 0.638
AG+GG vs. AA 0.210 0.604 0.630 0.050
GG vs. AA 0.041 0.628 0.751 0.026
rs646776 A>G-genotypes
TT 4.62 (4.07–5.35) 6.69 (0.97–12.47) 1.15 (0.44–1.85) 2.93 (2.37–3.47)
TC+CC 4.46 (3.61–5.31) 2.42 (1.12–6.24) 2.04 (0.48–2.36) 2.79 (1.87–3.69)
CC 4.69 (3.38–6.02) 2.30 (1.34–12.31) 2.16 (1.54–2.78) 2.52 (1.73–3.30)
TC 4.52 (3.02–6.04) 3.54 (0.72–8.09) 1.44 (1.21–2.77) 2.53 (1.74–3.33)
TT+TC 4.61 (3.37–5.98) 4.52 (0.88–9.29) 1.36 (0.95–1.76) 2.64 (1.98–3.30)
𝑃 value for rs646776 genotypes
TC+CC vs. TT 0.590 0.250 0.041 0.272
CC vs. TT+TC 0.972 0.087 0.021 0.252
CC vs. TT 0.906 0.018 0.004 0.427
rs4970834 C>T-genotypes
CC 4.92 (4.12–5.72) 3.11 (1.18–8.16) 1.51 (0.94–2.07) 3.32 (2.48–4.15)
CT+TT 4.39 (3.66–5.13) 2.78 (1.69–7.69) 1.44 (1.02–1.87) 2.99 (2.36–3.63)
TT 4.19 (3.85–5.54) 2.42 (0.97–6.56) 1.38 (0.79–1.97) 2.74 (2.19–3.29)
CT 4.62 (3.45–5.81) 2.64 (0.77–6.98) 1.48 (0.92–1.98) 3.10 (2.45–3.75)
CC+CT 4.75 (3.62–5.87) 2.87 (1.02–7.15) 1.46 (0.86–2.01) 3.01 (2.47–3.73)
𝑃 value for rs4970834 genotypes
CC vs. CT+TT 0.311 0.845 0.757 0.792
TT vs. CT+CC 0.880 0.852 0.657 0.165
CC vs. TT 0.752 0.912 0.812 0.386
Analysis of variance by general linear model with adjusted age, gender, BMI, type 2 diabetes, smoking, hypertension, and lipid-lowering therapy. LDL-C: low-
density lipoprotein cholesterol and HDL-C: high-density lipoprotein cholesterol. Two-tailed 𝑃 value is significant at <0.05.
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Table 4: Stepwise regression analysis for LDL-C (dependent) and selected independent variables; age, gender, BMI, diabetes, and
antilipidemic treatment (statin) and rs599839, rs646776, and rs4970834.
Independent variable 𝛽-coefficient Standard coefficient Standard error 𝑃 value
Age −0.016 −0.510 0.032 0.706
Gender 0.840 0.516 1.627 0.611
BMI 0.132 2.38 0.056 0.028
Diabetic state −0.558 −0.240 0.168 0.005
Smoking 0.038 0.062 0.617 0.951
Statin 0.570 1.146 0.497 0.266
rs4970834 0.337 0.493 0.684 0.627
rs646776 0.065 0.020 0.246 0.791
rs599839 1.74 2.69 0.646 0.014
𝑃 < 0.05 is significant for levels of 𝛽-coefficient at 2-tailed testing.
(2.30 versus 6.69mM, 𝑃 = 0.018) and higher HDL-C
compared to TT carriers (2.16 versus 1.15mM, 𝑃 = 0.004),
respectively.Theminor allele (T) of variant rs4970834 had no
effect on any lipid parameter as shown in Table 3. The minor
allele “G” of rs599839 was associated with a decreased LDL-
C level of 0.2–0.3mmol/L per allele, and with an increase by
0.08–0.18mmol/LwithHDL-C andwith a decreased TC level
of 0.23–0.98mmol/L per allele. In addition, the minor allele
C of rs646776 was also associated with an increase of HDL-
level of 0.15–0.25mmol/L per allele. The minor allele T of
rs4970834was not associatedwith a decreased LDL-C level of
0.33–0.58mmol/L per allele and decreased 0.07–0.13mmol/L
with HDL-C.
4.2.2. Associations between LDL-C, Genotype, and Cardiac
Risk Factors Associated with the CAD of the Study Subjects
(Table 4). Furthermore, we quantify the effect of the geno-
type and phenotypes associated with the risks of the CAD on
the circulating LDL-C level. The stepwise regression analysis
was performed to discriminate the significant effect of the
following independent variables: age, gender, obesity, diabetic
state, smoking, and statin treatment and rs599839, rs646776,
and rs4970834 in their dominant mode on the dependent
factor LDL-C among all CAD patients. The results show
that the following independent variables have a statistically
significant effect on LDL-C level, BMI (𝑃 = 0.028), diabetes
(𝑃 = 0.005), and rs599839 (𝑃 = 0.014) as shown in Table 4
and contribute to 37.7% of LDL-C level among the study
subjects. However, the regression analysis suffered from the
problem of multicollinearity which is essentially a problem
of correlated independent variables.
4.3. Association of rs599839, rs64776, and rs4970834 Geno-
types with Angiographically Characterized CAD Patients
4.3.1. Associations between SNPs Genotype and Degree of
Coronary Stenosis (Table 5). Table 5 presents the associations
between the angiographic characters of coronary vessels
stenosis with the variants rs599839, rs64776, and rs4970834
utilizing the logistic regression analysis. The stepwise regres-
sion models were used as follows: model 1 is unadjusted,
model 2 is adjusted for age, gender, obesity, hypertension,
Table 5: Results from logistic regression analysis: associations
between determined SNPs and significant coronary stenosis for
carriers of the rare allele compared to carriers of the homozygous
common allele.
SNP Model OR 95% CI 𝑃 value
rs599839
Model 1 0.59 0.34–0.97 0.049
Model 2 0.56 0.32–0.94 0.043
Model 3 0.51 0.30–0.92 0.038
rs646776
Model 1 0.62 0.27–1.43 0.263
Model 2 0.55 0.21–1.46 0.227
Model 3 0.53 0.19–1.45 0.213
rs4970834
Model 1 0.98 0.57–1.68 0.944
Model 2 0.83 0.45–1.51 0.545
Model 3 0.88 0.46–1.70 0.705
Three logistic regression models were built: model 1 remained unadjusted,
model 2 adjusted for age, gender, obesity, hypertension, diabetes, smoking,
and family history of CAD, and model 3 for the covariates adjusted in model
2 and additionally LDL, HDL, and statin. OR, odds ratio, and CI, confidence
interval. Two-tailed 𝑃 value is significant at <0.05.
diabetes, smoking, and family history of CAD, and model
3 for the cofounders adjusted in model 2 with LDL, HDL,
and lipid-lowering treatment. Only the association between
the G allele of rs599839 with CAD is significant even after
adjustment for the cofounders counted inmodel 2 andmodel
3.The unadjusted odds ratio and 95% CI of the G allele of the
variant rs599839 were 0.59 (0.34–0.97), 𝑃 = 0.049 and after
adjustment were 0.56 (0.32–0.94), 𝑃 = 0.043 and 0.51 (0.30–
0.92), 𝑃 = 0.38 for models 2 and 3, respectively, indicating
reduced risk for CAD stenosis.
We evaluated the possible assocaition of diabetes and
statin with the variants rs599839, rs64776, and rs4970834 in
ACS patients. We separated the ACS patients based on the
presence and absence of diabetes and the use of statin or
not. Using the same logistic regression models applied as
above, the odds ratio were not significantly different between
patients receiving statin and those not receiving statin therapy
(data not shown). Next, we quantified the contribution of
genetic SNPs (Dominant model; rare alleles carriers versus
the common homozygous allele carriers) with the traditional
CVD risks on the significant stenosis in ACS patients. These
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Table 6: Estimated haplotype frequency of the rs599839, rs646776, and rs4970834 polymorphisms in chromosomal locus 1p13.3 and its
associations with the severity of coronary artery lesion in coronary artery disease (CAD) patients for significant stenosis versus nonsignificant
stenosis outcome.
rs599839 rs4970834 rs646776 Haplotype EM frequency
≥50%
EM frequency
<50%
Adjusted OR,
95% Cl 𝑃 valueA G C T T C
A G C T T C ATC 0.284 0.364 0.69(0.46–1.05) 0.090
A G C T T C GTC 0.295 0.178 0.54(0.21–0.96) 0.005
A G C T T C ACC 0.186 0.219 0.82(0.51–1.32) 0.410
A G C T T C GCC 0.093 0.135 0.66(0.36–1.21) 0.172
A G C T T C GCT 0.061 0.034 1.85(0.70–4.89) 0.208
A G C T T C ATT 0.043 0.058 0.73(0.30–1.74) 0.471
A G C T T C GTT 0.028 0.007 4.00(0.58–27.57) 0.128
Data are presented as frequency for severity of coronary artery lesion in CAD patients with significant lesion (≥50%) versus insignificant stenosis (<50%) for
each haplotype with the odds ratio, lower and upper 95% confidence intervals, and 𝑃 value. The data were analyzed by logistic regression analysis. ORs were
adjusted for age, gender, BMI, type 2 diabetes, smoking, hypertension, and lipid-lowering therapy. Two-tailed 𝑃 value is significant <0.05.
independent CVD factors included: old age above 60, male
gender, obesity, DM, hypertension, smoking, serum LDL-
C above the desirable level, and statin treatment. A logistic
regression analysis was performed where these CVD factors
were involved as independet factors to highlight its effect on
the response variable (dependent) of the significant lesion
(≥50%) versus the non-significant stenosis (<50%) in theACS
patients. The results show that diabetes increases the odds by
2.02 (1.03–3.96), 𝑃 = 0.039 and carriers of the minor alleles
of rs599839 decreases the risk with odds of 0.78 (0.55–0.97),
𝑃 = 0.033 and this model may explain 17.8% of the model
effect, as shown in Figure 2.
4.3.2. Haplotype Frequency and Its Association with (Table 6).
The alleles of the SNPs (rs599839, rs4970834, and rs646776)
in order located in chromosomal locus 1p13.3 formed several
frequent haplotypes with their associations, as shown in
Table 6. Only the GTC haplotype formed by the rare alleles
of the studied SNPs had a significant protective effect against
the risk of the stenosis of coronary arteries in CAD with
odds ratio 0.54 and 95% CI = 0.21–0.96. Its frequency in
significant stenosis is nearly 1.8 times (29.5% versus 17.8%,𝑃 =
0.005) its frequency in nonsignificant stenosis, respectively.
In addition, the other haplotypes formed had an insignificant
effect on the risk of vessels stenosis, as shown in Table 6.
4.4. The Biological Interaction of High LDL-C and Genetic
Variants at 1p13 Locos on Stenosis Severity of ACS Patients
Expressed as Odds Ratio (OR) and 95% CI in ACS Patients
(Table 7). Given the causal association between high serum
LDL and coronary stenosis in ACS, we tested the biological
interaction between the genotypes and the serum level
of LDL-C as an important player in the pathogenesis of
Table 7: Effect of interaction between serum LDL-C and genetic
variants at Ip13.3 locus on the risk of significant coronary stenosis in
ACS patients.
SNP Model OR 95% CI
Synergy
index (𝑆)
with 95% CI
High LDL 1.27 0.68–1.97
rs599839 AG+GG vs. AA 0.59 0.34–1.02
Both 0.87 0.36–2.13 0.41(0.15–1.14)
High LDL 1.27 0.68–1.97
rs646776 TC+CC vs. TT 0.62 0.27–1.43
Both 1.01 0.26–3.95 0.57(0.21–1.54)
High LDL 1.27 0.68–1.97
rs4970834 CT+TT vs. CC 0.98 0.57–1.68
Both 1.04 0.45–2.40 0.43(0.15–1.27)
Data are presented by OR and 95 % CI. Both means high LDL and genetic
model effect on risk of stenosis, calculated by logistic regression analysis (see
stat analysis). Synergy index (𝑆) with 95% CI is biological measure of the
interaction between two effects on one biological parameter, and if 𝑆 below 1
means it is antagonistic and if above 1 suggests synergistic or additive.
the coronary artery stenosis and its severity in ACS patients.
An antagonismwas detected between the G allele at rs599839
and the exposure to high serum level of LDL-C, with
calculated synergy index (S) of 0.41 (0.15–1.14) between
the interaction terms as shown in Table 7. Furthermore,
the interaction between the rare alleles of rs646776 and
rs4970834 suggested the presence of antagonistic effect with
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Figure 2: Logistic regression analysis of the factors involved as confounding factors on the response variable of the significant lesion (≥50%)
versus nonsignificant stenosis (<50%) in all ACS patients. Data are presented as odds ratio and 95% CI. Data show the effects of CVD risk
factors (genetic variants (in their dominant model)) in interaction with traditional CVD risks including the following variables: old age above
60, male gender, +obesity, +DM, +hypertension, +smoker, +hyper-LDL-C above desirable level, and statin treatment on severity of significant
stenosis of the coronaries in the study subjects. Two-tailed P value is significant < 0.05.
an S 0.57 (0.21–1.54) and S 0.43 (0.15–1.27), but with a larger
95% CI, respectively.
5. Discussion
In this study, we examined the association among LDL-C,
the coronary artery stenosis, and the 3 genetic variations
rs599839, rs4970834, and rs646776 on the chromosomal
locus 1p13.3. The study was carried on in a well-defined
Arab population presenting with ACS. The main findings
of this study are as follows: (1) the G allele carrier of the
variant rs599839 had a significant protective effect against
the risk of the significant atherosclerotic lesion in coronary
arteries, (2) the significant association of polymorphism
rs599839 (GG carriers) with lower LDL-C levels and total
cholesterol levels, and (3) the antagonismbetween theG allele
at rs599839 and the exposure to high serum level of LDL-
C. Moreover, the C-allele carriers of rs646776 variant had a
significant association with increased HDL-C. In addition,
the interaction between high LDL-Cwith the genetic variants
nearby SORT1 gene located in chromosomal locus 1p13.3
suggested the presence of antagonistic effect of the minor
alleles, G, C, and T of rs599839, rs64776, and rs4970834
(Table 7), and by the GTC haplotype formed by the minor
alleles of the studied SNPs (Table 6), respectively, on the
significant stenosis of the coronary arteries as outcome of
this interaction. The implications of these findings will be
discussed in the following paragraphs.
The SNP rs599839 in CELSR2-PSRC1-SORT1 on 1p13
revealed robust support for associations with LDL levels and
risk of ACS in our study. The current finding for rs599839 is
consistent with the results from previous studies in the Cau-
casian populations [14, 17, 33]. The GWAS of cardiovascular-
related quantitative traits in the Framingham Heart Study by
Roslin et al. (2009) reported associations between rs599839,
on chromosome 1p13 and LDL [34]. A recent study by Zhou
et al. (2011) demonstrated that rs599839 was significantly
associated with CHD liability in a Chinese Han population
with an effect on LDL through the risk A allele [35]. Sandhu
et al. (2008) identified that rs599839 was associated with LDL
levels using GAWS data from 11,685 European subjects [14].
Willer et al. (2008) described a correlation between rs599839
with both LDL levels and CHD risk in Caucasians [16].
Samani et al. (2008) reported an association of rs599839 with
LDL cholesterol with myocardial infarction (𝑃 = 0.0026)
[33]. The underlying mechanism through which rs599839,
rs646776, and rs4970834 affect LDL-C is notwell understood.
One possibility is that these SNPs or associated genetic mark-
ers may influence the expression of SORT1 gene that mediates
the endocytosis and degradation of lipoprotein lipase [36].
Musunuru et al. (2010) have suggested a functional proof
for this novel regulatory pathway for lipoprotein metabolism
and proposed that any change might modify the hazard for
myocardial infarction [37]. In addition,Angelakopoulou et al.
(2012) stated that SORT1 rs599839 was correlated with the
risk of CHD with odds ratio and 95% CI (1.20; 1.15–1.26) as
well as total and LDL cholesterol and Apolipoprotein B [38].
In addition, our study demonstrated that G allele car-
riers of rs599839 had lower LDL-C and C allele carrier of
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rs646776 had an effect on increasing the HDL-C, which acts
as scavenger lipoprotein that prevents the accumulation of
lipid contacting particles with could predispose to plaque
formation with high triglyceride levels. The current data is
consistent with earlier results by Muendlein et al. (2009)
which revealed that the rare alleles of variants rs599839,
rs646776, and rs4970834 were significantly correlated with
decreased serum LDL cholesterol (132 ± 40mg/dL versus 125
± 36mg/dL,𝑃 = 0.003, 132± 40mg/dL versus 124± 36mg/dL,
𝑃 < 0.001, and 131 ± 40mg/dL versus 125 ± 37mg/dL, 𝑃 =
0.005), respectively [17].
However, the discrepancy between the findings of our
study for rs4970834 and the previous results by Muendlein et
al, 2009 [17], could be due to difference in ethnic background,
population stratification, and sample size.
In addition, the current data provide further evidence of
involvement of genetic variants rs599839 that could affect the
LDL level among study subjects by multivariate regression
analysis. The logistic regression analysis in our study showed
that the variant rs599839 only could exert its effect indepen-
dently from the other variants rs646776 and rs4970834, and
such effect could be attributed to the low LD between these
SNPs among our study subjects. Overall, the present data
support the role of 1p13.3 locus on the level of LDL, which
could play a role as a genetic variant in the pathogenesis of
atherosclerotic in CAD patients.
The data presented here indicate a role of the chromo-
somal locus with the significant stenosis in all coronary
arteries, in line with earlier studies [18, 33]. The finding of
the current study supported the previous studies that showed
an association between 1p13.3 locus and CAD [16, 33, 34, 37,
38]. Logistic regression analysis and haplotype estimation in
the current study showed that the variant rs599839 exerted
its effect on CAD independently and with associations of
the other variants rs646776 and rs4970834. This may point
to a major role of variant rs599839 in atherogenesis. This
finding needs further investigation to clarify the mechanisms
behind the association of rs599839 with atherogenesis in
CAD patients.
The current study showed low pairwise LD values
between the studies SNPs,which is different fromother popu-
lations such as the Caucasian between rs599839 and rs646776
(𝑟2 = 0.51) (http://www.hapmap.org/) meaning that this
locus has a different genetic structure in Arab population. In
addition the current study showed that the G allele frequency
in rs599839 (0.43), C allele of rs646776 (0.20), and T allele
of rs49708934 (0.37) are different than that reported for
other populations (http://www.hapmap.org/). This variation
may be due to due to the difference in ethnic background,
population stratification, and sample size. Such findings may
explain the discrepancies in the genetic effect on diseases
among different ethnic populations and need further studies.
Moreover, the current data showed an interesting finding
that the G allele carriers of rs599839 variant decrease the
severity of coronary stenosis using the dominant genetic
models independent of the dyslipidemia. This does not
primarily indicate that the A allele carriers of rs599839
polymorphism commence cardiovascular risk by itself indi-
vidually from its impact on total cholesterol and LDL
cholesterol levels. Definitely, a genotype, which is correlated
with cholesterol and LDL cholesterol, may reveal previous
and permanent exposure to LDL cholesterol better than the
current LDL cholesterol levels themselves, particularly in
CAD patients with the use of lipid-lowering and antidiabetic
medication. This postulation is reinforced by the fact that
LDL cholesterol serum concentrations were not significantly
different between 2 groups in our study and statin and
diabetes have no effect on the severity of stenosis in our
ACS patients. This finding may suggest a strong relationship
between the polymorphisms on chromosomal locus 1p13.3
and LDL cholesterol. The genetic polymorphisms at locus
1p13 and lipid profile may contribute in the same underlying
pathogenesis that leads to atherosclerosis and CAD. This
finding is consistent with previous reports indicating the
decrease of LDL-C and total cholesterol in carriers of the
minor allele G of rs599839 may decrease the severity of CAD
and risk ofMI among other ethnic populations [14, 32, 33, 36].
Furthermore, we evaluated this assumption by examination
of the biological interaction between genetic markers at locus
1p13.3 and high serum LDL-C because they contribute to the
same underlying pathogenesis that leads to atherogenesis and
CAD. The findings of the current study found that studied
variants at the locus 1p13.3 antagonize the risk of significant
stenosis due to the exposure to high LDL-C. These data are
in line with previous studies in GWAS [16, 33] and in SHEEP
studies [32].
This study has several limitations; one of the most
important is the sample size due to relatively small number of
populations in Qatar. The selection of the studied SNPs to be
explored in the current study relies on previously published
data and does not include other tagged SNPs associated
with the lipid profile such as rs611917 and rs12740374. The
phenotypes under study (CAD stenosis and LDL-C level)
are composite and might include different size effects of
the polygenic/environmental/genes interactions. As such, the
data may be biased and in addition to the small sample size
of the current studymay explain why other variants rs646776
and rs4970834 did not show significant associations with the
significant stenosis of CAD in our study.
6. Summary and Conclusion
Polymorphism of rs599839 is significantly associated with
LDL-C levels. In addition, the variant rs599839 has a signif-
icant association with the significant atherosclerotic lesion
in coronary vessels. Moreover, polymorphisms of rs599839,
rs646776, and rs4970834 at the locus 1p13.3 antagonize the
risk of significant stenosis caused by the exposure to high
LDL-C.
Future longitudinal studies in healthy populations are
necessary among the Qatari people to explore the role of such
locus and others variants for atherogenesis.
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